Inhaled Epinephrine for Anaphylaxis
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial investigates how inhaled epinephrine can assist individuals experiencing severe allergic reactions (systemic allergic reactions) after allergy testing, oral challenges, or immunotherapy treatments. The goal is to determine if inhaling this medication can quickly reduce symptoms without requiring an injection. It suits individuals aged 12 years or older with a history of allergies and significant allergic reactions during these procedures. This trial may interest those seeking an alternative to injections during allergic episodes. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this innovative approach.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the study team or your doctor.
Is there any evidence suggesting that inhaled epinephrine is likely to be safe for humans?
Research has shown that inhaled epinephrine is usually well-tolerated. One study found that it quickly spreads the medicine throughout the body and has noticeable effects in healthy volunteers, indicating that most people can use it without major problems.
Another review indicates that using epinephrine for severe allergic reactions, like anaphylaxis, is safe. Early use is important because it helps stop symptoms and lowers the chance of recurrence.
While strong evidence supports the safety of epinephrine in general, this trial is in its early stages. It primarily focuses on understanding the safety of inhaled epinephrine for people.12345Why do researchers think this study treatment might be promising?
Inhaled epinephrine is unique because it offers a new delivery method for treating anaphylaxis, potentially providing quicker relief compared to the traditional intramuscular injection. This inhalation approach could make it easier for patients to administer the treatment themselves during an allergic reaction. Researchers are excited about this treatment because it could simplify the process and improve the speed of symptom resolution, making it a game-changer for those who suffer from severe allergies.
What evidence suggests that inhaled epinephrine might be an effective treatment for systemic allergic reactions?
Research shows that inhaled epinephrine, which participants in this trial will receive, could be a promising treatment for severe allergic reactions. Studies have found that other forms of epinephrine, such as nasal sprays, are effective and easy to use for these conditions. This suggests that inhaled epinephrine might work similarly. Evidence from other delivery methods of epinephrine has demonstrated rapid symptom relief, often within minutes. Although direct data on inhaled epinephrine is limited, these findings support its potential effectiveness in managing allergic reactions.678910
Who Is on the Research Team?
George H. Luciuk, MD
Principal Investigator
Kokua Pharma Inc.
Are You a Good Fit for This Trial?
This trial is for individuals experiencing systemic allergic reactions during allergy testing, immunotherapy, or oral challenges. Specific eligibility criteria are not provided, but typically participants would have a history of allergies or anaphylaxis.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive inhaled epinephrine during systemic allergic reactions
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Inhaled Epinephrine
Trial Overview
The study investigates the effects of inhaled epinephrine on people having allergic reactions that aren't severe enough for another trial (GHL-101). It's exploratory and includes those undergoing various allergy-related procedures.
How Is the Trial Designed?
1
Treatment groups
Experimental Treatment
The first inhalation will be administered as soon as possible (i.e., within approximately 30 seconds) following identification of a SAR Grade 2 or higher and confirmation of enrollment by the Principal Investigator. The second inhalation will be administered approximately 10 seconds later, and the subject will be observed for approximately 2 minutes for signs of symptom resolution. Inhalations will continue in this manner until either: 1. resolution of systemic symptoms (defined as a reduction in SAR Grade to ≤1), or 2. if maximum number of inhalations (8 inhalations) has not been reached, complete resolution of systemic symptoms (defined as reduction in SAR Grade to 0) without exceeding maximum 8 inhalations, or 3. administration of intra-muscular epinephrine, whichever occurs earlier.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Dr. George Luciuk
Lead Sponsor
Citations
Evidence update for the treatment of anaphylaxis - PMC
Coronial inquests have identified that the use of AAIs for anaphylaxis can therefore result in substantial underdosing, which may contribute to fatal outcomes.
A health economic analysis of noninjectable epinephrine ...
The base-case assumed exaggerated anaphylaxis fatality rates (50-fold increase) for using inhaled epinephrine given low certainty evidence in anaphylaxis and ...
3.
journals.lww.com
journals.lww.com/co-allergy/fulltext/2025/12000/epinephrine_nasal_spray_for_the_treatment_of.11.aspxEpinephrine nasal spray for the treatment of anaphylaxis:...
According to recent research, intranasal epinephrine represents an easy-to-use, effective, and well tolerated treatment for severe allergic reactions.
Innovations in the treatment of anaphylaxis: A review ...
Data from these studies indicate promising pharmacokinetic results comparable to those of the standard of outpatient emergency care (0.3-mg EAI) ...
Superior Efficacy of Epinephrine Nasal Spray for the Relief ...
Conclusions. Relative to a matched control group, patients receiving neffy as an initial treatment had lower symptom scores within 10 minutes. These data ...
Anaphylaxis - StatPearls - NCBI Bookshelf - NIH
If epinephrine is required, as in cases of anaphylaxis, complete resolution is noted. Emergency department observation for 4 hours is recommended.
Benefits of Epinephrine for Anaphylaxis Outweigh Potential ...
Therefore, the objective of this narrative review is to describe the safety of epinephrine when administered for the treatment of anaphylaxis.
Effects of Inhaled Epinephrine on Systemic Allergic ...
The purpose of this exploratory study is to evaluate the effects of inhaled epinephrine in patients with known or suspected metabisulfite sensitivity who ...
9.
investor.alkermes.com
investor.alkermes.com/news-releases/news-release-details/alkermes-presents-positive-clinical-data-inhaled-formAlkermes Presents Positive Clinical Data for Inhaled Form ...
AIR Epinephrine demonstrated rapid systemic delivery associated with clinically meaningful pharmacodynamic responses in normal volunteers.
Anaphylaxis: A 2023 practice parameter update
Available evidence suggests that early epinephrine use for anaphylaxis may improve clinical outcomes by decreasing risk of biphasic reactions ...
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.